• Investors may be wondering whether Globus Medical at around US$84.81 is offering good value right now, or whether the recent excitement has already been priced in.
• The stock has had a mixed run recently, up 10.7% over the past week, while down 10.7% over the past month and down 2.9% year to date. It has also delivered a 43.8% return over the past year and 60.2% over three years.
• These moves have kept Globus Medical on many investors' radars as broader interest in medical technology and healthcare solutions continues to draw attention to the sector. At the same time, long term performance figures, including a 17.7% return over five years, provide additional context for the stock's recent swings.
• On Simply Wall St's valuation model, Globus Medical scores a full 6 out of 6 on the undervaluation checks. The next step is to walk through how different valuation approaches compare for this stock and then look at a more complete way to think about valuation that ties everything together.

Approach 1: Globus Medical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company's future cash flows and then discounts them back to today to estimate what the business might be worth right now.

For Globus Medical, the model used is a 2 Stage Free Cash Flow to Equity approach. The company currently reports last twelve month free cash flow of about $620.8 million. Analysts provide explicit free cash flow estimates out to 2028, with Simply Wall St extrapolating further years. Within these projections, free cash flow is expected to be $449.4 million in 2026 and $785.6 million in 2028, with values extending out to 2035 in the model, all expressed in $.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of $155.50 per share. Compared with the recent share price of about $84.81, this suggests the stock appears materially undervalued based on this method, with an intrinsic discount of roughly 45.5%.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Globus Medical is undervalued by 45.5%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Globus Medical Price vs Earnings

For profitable companies, the P/E ratio is a useful shortcut because it links what you pay for the stock to the earnings that support that price. Higher growth expectations and lower perceived risk can justify a higher P/E, while slower growth or higher risk usually imply a lower, more cautious multiple.

Globus Medical currently trades on a P/E of 19.62x. That sits below the Medical Equipment industry average of 24.53x and well below the peer group average of 43.98x, which suggests the stock is priced more conservatively than many companies in its space.

Simply Wall St also provides a proprietary “Fair Ratio” of 24.73x. This is the P/E level that might be expected given factors such as Globus Medical's earnings profile, industry, profit margins, market cap and risk characteristics. This Fair Ratio goes further than simple industry or peer comparisons because it adjusts for company specific features rather than assuming all stocks should trade on the same benchmark.

Comparing the Fair Ratio of 24.73x with the current P/E of 19.62x suggests Globus Medical is trading below this implied fair level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Globus Medical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach a clear story about Globus Medical to specific assumptions for revenue, earnings, margins and fair value. You can then compare that fair value to the current share price to help you decide whether you see more upside or downside, with the system updating automatically as fresh news or earnings arrive. For example, you might align with a more optimistic Narrative that targets US$123.0 per share, a more cautious view closer to US$65.0, or the current analyst consensus of US$111.50, depending on how you interpret factors like robotics adoption, integration of NuVasive and Nevro, and international growth.

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.